Glenmede Trust CO Na Alnylam Pharmaceuticals, Inc. Transaction History

Glenmede Trust CO Na

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $365 - $471	2 Added 0.1%	2,037 $408,000
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $2,968 - $3,860	-16 Reduced 0.78%	2,035 $483,000
Q3 2022 Nov 16, 2022	BUY	$138.54 - $232.0 $969 - $1,624	7 Added 0.34%	2,051 $410,000
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $246,138 - $346,028	2,044 New	2,044 $298,000
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $23,364 - $27,930	-190 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $848 - $1,158	7 Added 3.83%	190 $27,000
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $208 - $312	-2 Reduced 1.08%	183 $27,000
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $11,593 - $16,341	185 New	185 $13,000
Q3 2018 Nov 15, 2018	SELL	$87.52 - $122.67 $15,316 - $21,467	-175 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $12,692 - $20,697	175	175 $0

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.